INMB - NASDAQ
INmune Bio, Inc.
$1.89
-1.3%INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
At a Glance
Live SnapshotINmune Bio, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
INmune Bio, Inc. Income Statement
INMB • NASDAQ
| INmune Bio, Inc. Income Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
14K | 155K | 374K | 181K | 11K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||
14K | 155K | 374K | 181K | 11K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||
(42.6M) | (29.9M) | (26.3M) | (29.3M) | (12.2M) | (7.8M) | (12.4M) | (981.5K) | (227.5K) | (48.9K) | |
(9.5M) | (9.6M) | (9.3M) | (8.8M) | (6.3M) | (4.5M) | (9.1M) | (546.1K) | (126K) | (48.9K) | |
(33.2M) | (20.3M) | (17.1M) | (20.5M) | (5.9M) | (3.3M) | (1.1M) | (435.4K) | (101.5K) | (0.0) | |
-42.6M | -29.7M | -26M | -29.2M | -12.2M | -7.8M | -12.4M | -981K | -227K | -48.9K | |
PRE-TAX INCOME | ||||||||||
(0.0) | (0.0) | (1.3M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | -2M | 0.0 | 0.0 | 77.7K | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (1K) | (0.0) | (0.0) | -6.0 | (0.0) | (0.0) | |
553K | -267K | -1.3M | -1.2M | 129K | 77.7K | 0.0 | 150K | -50K | 0.0 | |
-42.1M | -30M | -27.3M | -30.3M | -12.1M | -7.7M | -12.4M | -831K | -277K | -48.9K | |
NET INCOME | ||||||||||
-42.1M | -30M | -27.3M | -30.3M | -12.1M | -7.7M | -12.4M | -831K | -277K | -48.9K |
SEC Filings
INMB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | December 19, 2025 | December 19, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 10, 2025 | December 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 03, 2025 | December 02, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 28, 2025 | November 26, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 18, 2025 | November 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 30, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your INMB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.